By “Depression” is used as a single word for what is actually a family of related but clinically distinct conditions. The distinction matters enormously – not for academic classification, but because the type of depression determines the most appropriate treatment, the expected course, the risk factors for relapse, and what recovery looks like.
A person with seasonal affective disorder who responds dramatically to a light box may spend years on antidepressants if the seasonal pattern goes unrecognized. A person with bipolar depression who is prescribed an antidepressant without a mood stabilizer may be tipped into a manic episode that could have been avoided. Someone with persistent depressive disorder may have sought help for “feeling down” their whole adult life without recognizing that their baseline is not everyone’s baseline.
This article covers the major depressive conditions, what distinguishes each, and what the differences mean for treatment.
Major Depressive Disorder (MDD)
Major depressive disorder is what most people mean when they say “clinical depression” – the most common and most studied form.
The defining features: Discrete episodes of significant depression lasting at least two weeks, meeting five or more DSM-5 criteria (depressed mood, anhedonia, sleep changes, appetite changes, fatigue, concentration difficulties, psychomotor changes, guilt or worthlessness, suicidal thoughts). At least one criterion must be either depressed mood or anhedonia. Symptoms must cause meaningful functional impairment.
Single episode vs recurrent: MDD is classified as single-episode (one lifetime episode) or recurrent (two or more episodes). The majority of people who have one major depressive episode will have another. After two episodes, recurrence probability rises to approximately 70%; after three, to over 90% without ongoing treatment.
Severity specifiers: MDD is rated mild, moderate, or severe based on symptom count, intensity, and functional impact. Severity guides treatment intensity – mild-to-moderate depression may respond to psychotherapy alone; moderate-to-severe depression typically requires medication, often combined with therapy.
Psychotic features: A subset of severe MDD cases include psychotic symptoms – typically delusions or hallucinations that are mood-congruent (believing you’ve done something terrible, hearing voices that confirm this). This requires different treatment (antipsychotics alongside antidepressants) and typically responds to ECT.
Melancholic features: A specific subtype characterized by profound anhedonia, early morning awakening, mood that is worse in the morning, psychomotor disturbance, significant weight loss, and excessive guilt. Melancholic depression tends to respond better to medication than psychotherapy alone and has a distinct neurobiological profile.
Persistent Depressive Disorder (PDD / Dysthymia)
Persistent depressive disorder is chronic depression – depressive symptoms that have been continuously present for at least two years in adults (one year in adolescents), even if they don’t always reach the full severity threshold of MDD.
The key feature: Duration, not necessarily intensity. PDD is characterized by a chronically depressed mood that has been present for most of the day, more days than not, for years. It may wax and wane in intensity but never fully remits.
Symptoms required: Depressed mood plus at least two of: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, feelings of hopelessness.
Why it’s frequently missed: PDD is often not recognized because people adapt to it. When you’ve felt this way for years – or, in some cases, since adolescence – it can feel like just who you are. People with PDD often describe themselves as “a depressive person” or say they’ve “always been this way,” without recognizing that their persistent low mood and reduced functioning represents a treatable condition.
“Double depression”: When a major depressive episode occurs in someone with underlying PDD, this is called double depression. The MDD episode may resolve with treatment while PDD continues – which can feel like treatment failure when the acute episode improves but the chronic baseline depression persists.
Treatment: Both psychotherapy (particularly CBT and schema-focused therapy) and antidepressants are effective. The chronic nature of PDD means treatment typically needs to be longer than for single-episode MDD, and relapse prevention is a central focus.
Seasonal Affective Disorder (SAD)
Seasonal affective disorder is a form of depression that follows a predictable seasonal pattern, typically occurring in autumn and winter and remitting in spring and summer.
Prevalence and geography: SAD affects approximately 1-3% of the US population in its full form, with an additional 10-20% experiencing a milder version called “subsyndromal SAD” or “winter blues.” Prevalence increases with latitude – SAD is significantly more common in northern states than southern ones, consistent with its light-exposure hypothesis.
The mechanism: The key driver is reduced light exposure in winter months. Light is the primary signal that sets the circadian clock. Reduced light in autumn/winter:
- Increases melatonin secretion duration (the hormone that promotes sleep – more melatonin for longer = more sleepiness, more “hibernation” drive)
- Shifts circadian rhythms out of alignment with the social/work schedule
- Affects serotonin transporter activity (reduced light → increased serotonin reuptake → less available serotonin)
How SAD presents differently: SAD has a characteristic symptom profile that often differs from typical MDD – hypersomnia (sleeping too much rather than insomnia), hyperphagia (increased appetite, particularly carbohydrate craving, and weight gain), heavy/leaden feelings in the limbs, and excessive fatigue. This “atypical” pattern makes sense in the context of a biological hibernation response.
Treatment:
- Light therapy: The first-line treatment. A 10,000-lux light box (white light, UV-filtered) used for 20-30 minutes in the morning is as effective as antidepressants for SAD. Must be used consistently throughout the winter season.
- SSRIs: Equally effective to light therapy; many patients use both
- Vitamin D: Low vitamin D is associated with SAD and supplementation may help; addressing deficiency is worthwhile
- Behavioral: Exercise, maintaining regular sleep-wake timing, increasing outdoor light exposure
Postpartum Depression (PPD)
Postpartum depression is a major depressive episode occurring during pregnancy or within the weeks to months after childbirth. The DSM-5 uses the specifier “with peripartum onset” for episodes beginning during pregnancy or within four weeks of delivery; clinical practice typically extends the postpartum window to 12 months.
Baby blues vs PPD: The “baby blues” – mood lability, tearfulness, irritability, and emotional instability in the first week after delivery – affects up to 80% of new mothers and is normal, expected, and self-limiting (resolves within two weeks). PPD is distinct: it lasts beyond two weeks, is more severe, and meets criteria for a major depressive episode.
Prevalence: Approximately 10-15% of mothers develop PPD. It’s the most common complication of childbirth. Risk factors include prior history of depression or PPD, lack of social support, difficult relationship with partner, economic stress, birth complications, and breastfeeding difficulties.
Fathers and partners: Postpartum depression in fathers and non-birthing partners is real and frequently overlooked. Rates of approximately 4-10% have been documented, with higher rates in fathers whose partners have PPD. The combination of sleep deprivation, identity transition, relationship strain, and exclusion from social attention typically given to the mother creates genuine depression risk.
The hormonal factor: The dramatic postpartum drop in estrogen and progesterone is the most frequently cited biological trigger. Some women appear particularly neurobiologically sensitive to these hormonal shifts – interestingly, this is the same population that tends to experience significant PMDD (premenstrual dysphoric disorder). The FDA approved brexanolone (Zulresso) in 2019 – a synthetic neuroactive steroid targeting GABA-A receptors – specifically for PPD, and zuranolone (Zurzuvae) in 2023, reflecting the distinct hormonal pathophysiology of PPD.
Treatment:
- Psychotherapy (CBT and IPT have specific evidence for PPD)
- SSRIs and SNRIs (considered relatively safe during breastfeeding with careful risk-benefit assessment)
- Brexanolone or zuranolone for severe PPD
- Social support, sleep support, partner involvement
PPD goes undiagnosed far too often. The new mother narrative – joy, bonding, gratitude – doesn’t leave much space for “I feel nothing” or “I don’t recognize myself.” Screening with the Edinburgh Postnatal Depression Scale (EPDS) should be routine at all postpartum visits.
Premenstrual Dysphoric Disorder (PMDD)
PMDD is a severe form of PMS characterized by significant mood symptoms (depressed mood, hopelessness, irritability, anger, anxiety, emotional lability) that emerge in the week before menstruation and resolve within days of the period beginning.
What makes it different from PMS: Severity and functional impact. PMS is common and ranges from mild to moderate. PMDD involves symptoms severe enough to disrupt work, relationships, and daily function – and a quality of the symptoms that many women describe as feeling like a completely different person in the luteal phase.
Mechanism: PMDD is driven by abnormal neurological sensitivity to normal hormonal fluctuations – not by abnormal hormone levels. Women with PMDD have normal estrogen and progesterone levels; their brain responds differently to progesterone’s neurosteroid metabolite (allopregnanolone) than women without PMDD.
Treatment: SSRIs – either taken continuously or only during the luteal phase (typically the 14 days before menstruation) – are highly effective for PMDD and respond faster than for typical MDD. GnRH agonists (which suppress ovulation entirely) are a second-line option for severe cases.
Bipolar Depression
Bipolar disorder involves cycles of depression and mania (or hypomania in bipolar II). The depressive phase of bipolar disorder can look identical to MDD on presentation – but treatment differs fundamentally.
Why the distinction matters: Antidepressants used alone in bipolar depression can precipitate a manic or hypomanic episode, trigger rapid cycling (more frequent mood episodes), or produce a “mixed state” (simultaneous depressive and manic symptoms) – all of which worsen the overall course of bipolar disorder. The primary treatment for bipolar depression is mood stabilizers (lithium, valproate, lamotrigine) and/or atypical antipsychotics – not antidepressants alone.
How to distinguish: Before diagnosing MDD and prescribing antidepressants, screening for any lifetime history of mania or hypomania is essential. The MDQ (Mood Disorder Questionnaire) is a validated screening tool. Key questions: Have you ever had periods of unusual energy, reduced need for sleep, racing thoughts, grandiosity, or impulsive behavior that felt distinctly different from your normal? Any history of psychiatric hospitalization, reckless behavior during an elevated mood state, or family history of bipolar disorder warrants careful assessment.
Bipolar I vs Bipolar II:
- Bipolar I: Full manic episodes (lasting at least 7 days, often requiring hospitalization)
- Bipolar II: Hypomanic episodes (less severe than full mania, not requiring hospitalization) alternating with major depressive episodes. Bipolar II is frequently misdiagnosed as recurrent MDD because the hypomanic episodes can be brief and may not be reported by the patient as problematic.
Treatment-Resistant Depression (TRD)
Treatment-resistant depression is defined as MDD that has failed to adequately respond to at least two adequate trials of antidepressant medications (adequate dose, adequate duration – at least 6-8 weeks).
Approximately 30-40% of people with MDD don’t achieve remission with the first antidepressant tried. About one-third of depressed patients don’t achieve remission even after multiple adequate treatment trials.
Options for TRD include: augmentation strategies (adding lithium, atypical antipsychotics, or thyroid hormone to antidepressants), switching medication classes, ketamine/esketamine, TMS, ECT, and newer approaches including psychedelic-assisted therapy (psilocybin has significant clinical trial evidence for TRD and depression in cancer patients, though FDA approval was not granted as of 2025 and research continues).
Frequently Asked Questions
How does a doctor decide which type of depression I have? Through a comprehensive clinical assessment covering symptom pattern, timing, triggers, duration, prior episode history, family history, and screening for bipolar history. The seasonal pattern, presence of atypical features, relationship to the menstrual cycle, postpartum timing, and any history of elevated mood states all inform the diagnostic picture. It’s not always clear-cut – and diagnostic reconsideration is appropriate when treatment response doesn’t match expectations.
Can you have more than one type of depression at once? Yes. “Double depression” (MDD superimposed on PDD) is common. Someone with PDD can have major depressive episodes that rise above their already-low baseline. Someone with seasonal depression may have a baseline PDD that worsens dramatically in winter. Comorbidity is the rule rather than the exception in mental health.
Is treatment different for each type? Yes, meaningfully so in some cases. Light therapy is specifically targeted at SAD. SSRIs in the luteal phase specifically target PMDD. Mood stabilizers are required for bipolar depression. Hormonal treatments (brexanolone, zuranolone) specifically target PPD. The antidepressant-first approach that works well for MDD can be harmful in bipolar depression. Getting the subtype right matters for treatment selection.
Can I have depression and not feel sad? Yes – this is one of the most important points about depression. Anhedonia (loss of pleasure and interest) is the other core symptom alongside depressed mood, and some people with depression experience primarily the anhedonia, fatigue, concentration problems, and functional impairment without pronounced sadness. Men in particular more often present with irritability, anger, and withdrawal than with visible sadness, which contributes to underdiagnosis in men.
If I have one type of depression, am I more likely to develop another? Some types are related. PMDD is associated with higher rates of PPD. PDD increases the risk of MDD episodes. People with SAD often have underlying vulnerability to depression. A history of any depressive disorder is the strongest predictor of future depressive episodes.
If You’re Struggling Right Now
If you are experiencing depression or thoughts of suicide or self-harm, please reach out.
988 Suicide and Crisis Lifeline: Call or text 988 (US) – available 24/7, free and confidential. Crisis Text Line: Text HOME to 741741
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Diagnosis and treatment of depressive disorders should be conducted by qualified mental health professionals. Do not adjust or discontinue medications based on this content without medical supervision.
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Arlington, VA: APA; 2013.
- Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. American Journal of Psychiatry. 2000;157(6):924-930. https://doi.org/10.1176/appi.ajp.157.6.924
- Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry. 1984;41(1):72-80. https://doi.org/10.1001/archpsyc.1984.01790120076010
- Yonkers KA, O’Brien PM, Eriksson E. Premenstrual syndrome. The Lancet. 2008;371(9619):1200-1210. https://doi.org/10.1016/S0140-6736(08)60527-9
- Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490-498. https://doi.org/10.1001/jamapsychiatry.2013.87
- Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry. 2000;157(11):1873-1875. https://doi.org/10.1176/appi.ajp.157.11.1873
- National Institute of Mental Health (NIMH). Depression. https://www.nimh.nih.gov/health/topics/depression
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps (STAR*D report). American Journal of Psychiatry. 2006;163(11):1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
- American Psychological Association. Bipolar disorder. https://www.apa.org/topics/bipolar-disorder
- Bauer M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. World Journal of Biological Psychiatry. 2010;11(2):81-109. https://doi.org/10.3109/15622970903560961